Posted on | Posted on John Murphy | Leave a Comment on A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Authors: Sabeena Ahmed 1, Mohammad Mahbubul Karim 1, Allen G Ross 1, Mohammad Sharif Hossain 1, John D Clemens 1, Mariya Kibtiya Sumiya 1, Ching Swe Phru 1, Mustafizur Rahman 1, Khalequ Zaman 1, Jyoti Somani 2, Rubina Yasmin 3, Mohammad Abul Hasnat 4, Ahmedul Kabir 5, Asma Binte Aziz 1, Wasif Ali Khan 6 Abstract Ivermectin, a US…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Authors: Andrew Bryant, MSc,1,* Theresa A. Lawrie, MBBCh, PhD,2 Therese Dowswell, PhD,2 Edmund J. Fordham, PhD,2 Scott Mitchell, MBChB, MRCS,3 Sarah R. Hill, PhD,1 and Tony C. Tham, MD, FRCP4 Background: Repurposed medicines may have a role…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows

Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows

Authors: COVID-19 Media Briefing with Dr. Adnan Munkarah DETROIT – Treatment with hydroxychloroquine cut the death rate significantly in sick patients hospitalized with COVID-19 – and without heart-related side-effects, according to a…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Authors: Philippe Gautret 1, Jean-Christophe Lagier 2, Philippe Parola 1, Van Thuan Hoang 3, Line Meddeb 4, Morgane Mailhe 4, Barbara Doudier 4, Johan Courjon 5, Valérie Giordanengo 6, Vera Esteves Vieira 4, Hervé Tissot Dupont 2, Stéphane Honoré 7, Philippe Colson 2, Eric Chabrière 2, Bernard La Scola 2, Jean-Marc Rolain 2, Philippe Brouqui 2, Didier Raoult 8 Abstract Background: Chloroquine and hydroxychloroquine have been…[...]

Read More